Trevena Announces Completion of Phase 1 Study for TRV045, Novel S1P Receptor Modulator
09.11.2022 - TRV045 demonstrated a favorable tolerability profile with no reported SAEs and no lymphopenia Nonclinical study showed anti-inflammatory signaling, suggesting a potential disease-modifying effect of TRV045 in the treatment of epilepsy, based on ... Seite 1
Carrie Bourdow Trevena Inc National Institutes Of Health Clinical Program National Institutes Single Ascending Dose
Source: wallstreet-online.de